Mayo Clinic

TORONTO – October 14, 2026 -- Patients treated with whole-gland TULSA were more than twice as likely to preserve both erectile function and pad-free continence at six months as those who had robotic radical prostatectomy (risk ratio 2.1; p=0.004), according to CAPTAIN trial data. Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) presented the results among five abstracts at the 15th Interventional MRI Symposium in Boston.

CAPTAIN trial shows whole-gland TULSA cut complication hospitalizations to 0.7% versus 6.3% for robotic surgery

CAPTAIN is the first fully enrolled, multicenter randomized controlled trial to compare the TULSA Procedure directly with robotic radical prostatectomy in localized intermediate-risk prostate cancer. Whole-gland TULSA also showed statistically superior preservation of flaccid penile length at one month.

Berlin – September 16, 2026 -- Aignostics has opened early access to PathoSearch, a visual search engine that retrieves diagnosed reference pathology cases from a single screenshot of an H&E slide, targeting the rare and complex cases that make up as much as 20% of a pathologist's caseload.

Database already spans 310,000 slides across 300 diagnostic entities

PathoSearch currently references more than 310,000 whole slide images drawn from over 35,000 cases, covering 300-plus diagnostic entities and 27-plus organs. The system is on track to exceed one million whole slide images by general availability. Coverage follows the WHO Classification of Tumours, focusing on malignant tumours across five organ groups -- thoracic, digestive, soft tissue and bone, female genital, and urinary and male genital -- with full coverage of all WHO-classified malignancies planned.

San Francisco – September 07, 2026 -- Rainfall Health announced that Mayo Clinic in Jacksonville, Florida will deploy its AI-driven platform to manage care coordination and compliance under the Centers for Medicare & Medicaid Services' Transforming Episode Accountability Model (TEAM), a mandatory payment program that took effect January 1, 2026.

CMS mandates 721 hospitals into value-based surgical episode program

CMS selected 721 hospitals for the first TEAM cohort, requiring value-based reimbursement across five high-volume surgical episodes. Hospitals missing cost and quality benchmarks face financial penalties, while those that meet targets can access reconciliation bonuses worth up to $85 million in new revenue.

New York – September 07, 2026 -- Bayesian Health has secured a New Technology Add-on Payment (NTAP) from the Centers for Medicare and Medicaid Services, making it the first continuous sepsis monitoring technology to hold both FDA clearance and a dedicated Medicare reimbursement pathway.

The approval, issued under CMS's FY 2027 Inpatient Prospective Payment System Final Rule, takes effect October 1, 2026, and allows hospitals using Bayesian's FDA-cleared sepsis flagging device to bill Medicare an add-on payment of up to $61.84 per eligible inpatient case.